The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease

B. R. Bloem*, W. J. Marks, A. L. Silva de Lima, M. L. Kuijf, T. van Laar, B. P. F. Jacobs, M. M. Verbeek, R. C. Helmich, B. P. van de Warrenburg, L. J. W. Evers, J. IntHout, T. van de Zande, T. M. Snyder, R. Kapur, M. J. Meinders

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

39 Citations (Web of Science)

Abstract

Background: Our understanding of the etiology, pathophysiology, phenotypic diversity, and progression of Parkinson's disease has stagnated. Consequently, patients do not receive the best care, leading to unnecessary disability, and to mounting costs for society. The Personalized Parkinson Project (PPP) proposes an unbiased approach to biomarker development with multiple biomarkers measured longitudinally. Our main aims are: (a) to perform a set of hypothesis-driven analyses on the comprehensive dataset, correlating established and novel biomarkers to the rate of disease progression and to treatment response; and (b) to create a widely accessible dataset for discovery of novel biomarkers and new targets for therapeutic interventions in Parkinson's disease.

Methods/design: This is a prospective, longitudinal, single-center cohort study. The cohort will comprise 650 persons with Parkinson's disease. The inclusion criteria are purposely broad: age >= 18 years; and disease duration

Discussion: The PPP has several distinguishing elements: all assessments are done in a single center; inclusion of "real life" subjects; deep and repeated multi-dimensional phenotyping; and continuous monitoring with a wearable device for 2 years. Also, the PPP is powered by privacy and security by design, allowing for data sharing with scientists worldwide respecting participants' privacy. The data are expected to open the way for important new insights, including identification of biomarkers to predict differences in prognosis and treatment response between patients. Our long-term aim is to improve existing treatments, develop new therapeutic approaches, and offer Parkinson's disease patients a more personalized disease management approach.

Original languageEnglish
Article number160
Number of pages10
JournalBMC Neurology
Volume19
DOIs
Publication statusPublished - 17 Jul 2019

Keywords

  • Cohort studies
  • Parkinson's disease
  • Biomarkers
  • Disease progression
  • Wearable device
  • MILD COGNITIVE IMPAIRMENT
  • VALIDITY
  • QUESTIONNAIRE
  • RELIABILITY
  • SLEEPINESS
  • SUBTYPES
  • SCALES
  • CARE

Cite this